/R E P E A T -- Media advisory - Transat A.T. Inc. - Third quarter results 2020/
MONTREAL, Sept. 3, 2020 /CNW Telbec/ - Transat A.T. Inc., a leading integrated international tourism company specializing in holiday travel and active in air transportation, accommodation, travel packaging and distribution, will release its Third quarter 2020 (ended July 31) results on September 10. Jean-Marc Eustache, Chairman of the Board, President, and Chief Executive Officer, Annick Guérard, Chief Operating Officer and Denis Pétrin, Vice-President, Finance and Administration and Chief Financial Officer, invite financial analysts to take part in a conference call the same day. Business reporters are welcome to attend the conference call in listen-only mode.
Third quarter 2020 conference Call: Thursday, September 10, 2020, 10:00 A.M. Dial 1-800-926-9801 or 1?212?231?2921 Name of conference: Transat Webcast: click here to register.
The archived call will be available at 416-626-4100 or 1-800-558-5253 access code 21951702, until October 9, 2020.
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...
Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New...
Regenx Tech Corp., (the "Company" or "Regenx") is providing this bi-weekly update on the status of the application to the Alberta Securities Commission for a management cease trade order, under National Policy 12-203 -?? Management Cease Trade...
Kadestone Capital Corp. ("Kadestone" or the "Company") , a vertically integrated property company today announced its financial results for the year ended December 31, 2023....
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...
